Damian Kovalovsky
Overview
Explore the profile of Damian Kovalovsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
853
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kovalovsky D, Noonepalle S, Suresh M, Kumar D, Berrigan M, Gajendran N, et al.
Sci Adv
. 2024 Nov;
10(46):eadp3687.
PMID: 39546602
Histone deacetylase 6 (HDAC6) inhibition is associated with an increased pro-inflammatory tumor microenvironment and antitumoral immune responses. Here, we show that the HDAC6 inhibitor AVS100 (SS208) had an antitumoral effect...
2.
Krzyzanowska A, Haynes Ii R, Kovalovsky D, Lin H, Osorio L, Edelblum K, et al.
Sci Immunol
. 2022 May;
7(71):eabf3717.
PMID: 35522722
The expression of BTB-ZF transcription factors such as ThPOK in CD4 T cells, Bcl6 in T follicular helper cells, and PLZF in natural killer T cells defines the fundamental nature...
3.
Voynova E, Hawk N, Flomerfelt F, Telford W, Gress R, Kanakry J, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158792
NK effector cells expressing a CAR construct may be used to target T-lineage markers. In this work, we compared the activity of a NK-specific CAR-NK and a CAR-T framework when...
4.
Voynova E, Kovalovsky D
Cells
. 2021 Nov;
10(11).
PMID: 34831068
Chimeric antigen receptor (CAR) T-cell therapy was envisioned as a mechanism to re-direct effector T-cells to eliminate tumor cells. CARs are composed of the variable region of an antibody that...
5.
Kovalovsky D, Yoon J, Cyr M, Simon S, Voynova E, Rader C, et al.
Leukemia
. 2021 Feb;
35(9):2581-2591.
PMID: 33633313
The only current curative treatment for chronic lymphocytic leukemia (CLL) is allogenic hematopoietic stem cell transplantation. Chimeric antigen receptor treatment targeting CD19 for CLL achieved some complete responses, suggesting the...
6.
Allen C, Lee S, Norberg S, Kovalovsky D, Ye H, Clavijo P, et al.
J Immunother Cancer
. 2019 May;
7(1):119.
PMID: 31053174
Background: Recurrent respiratory papillomatosis (RRP) is a human papillomavirus (HPV)-driven disorder that causes substantial morbidity and can lead to fatal distal airway obstruction and post-obstructive pneumonias. Patients require frequent surgical...
7.
Cao X, Ma X, Xue Y, Zeng Y, Zhang X, Lu Y, et al.
Cell Death Dis
. 2018 Oct;
9(10):1044.
PMID: 30310052
No abstract available.
8.
Cao X, Ma X, Du J, Zeng Y, Zhang X, Lu Y, et al.
J Cell Mol Med
. 2018 Jun;
22(8):4012-4015.
PMID: 29885067
No abstract available.
9.
Lu Y, Zhang X, Bouladoux N, Kaul S, Jin K, SantAngelo D, et al.
Oncotarget
. 2017 Sep;
8(34):55877-55888.
PMID: 28915559
Innate lymphoid cells (ILCs) play a central role conferring protection at the mucosal frontier. In this study, we have identified a requirement of the transcription factor Zbtb1 for the development...
10.
Zhang X, Lu Y, Cao X, Zhen T, Kovalovsky D
Oncotarget
. 2016 Aug;
7(37):58768-58778.
PMID: 27542215
Zbtb1 is a transcription factor that prevents DNA damage and p53-mediated apoptosis in replicating immune progenitors, affecting lymphoid as well as myeloid development when hematopoietic progenitors are in competition in...